# Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults

> **NCT06567457** · PHASE3 · WITHDRAWN · sponsor: **Clover Biopharmaceuticals AUS Pty**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
- **BIOLOGICAL:** SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

## Key facts

- **NCT ID:** NCT06567457
- **Lead sponsor:** Clover Biopharmaceuticals AUS Pty
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10
- **Primary completion:** 2024-09
- **Final completion:** 2024-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** varients of COVID-19 has changed
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567457, "Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06567457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*